Global Artificial Intelligence (AI) in Precision Medicine Market Research Report: Forecast (2026-2032)

The Global Artificial Intelligence (AI) in Precision Medicine Market Report Key Takeaways:

• Market size was valued at approximately USD 1.68 billion in 2025 and is projected to reach USD 10.32 billion by 2032. The estimated CAGR from 2026 to 2032 is around 35.33%, indicating strong growth.
• Oncology led the Global Artificial Intelligence (AI) in Precision Medicine market with 32.5% of total shares in 2025.
• In 2025, the Software segment captured 45% of the Global Artificial Intelligence (AI) in Precision Medicine market
• Leading companies in the Global Artificial Intelligence (AI) in Precision Medicine industry are Tempus, Intel Corporation, Zephyr AI, IBM, NVIDIA Corporation, Intuz, Google LLC, Persistent Systems, Owkin, Inc., and Others.

Market Insights & Analysis: Global Artificial Intelligence (AI) in Precision Medicine Market (2026-32):

The Global Artificial Intelligence (AI) in Precision Medicine Market size was valued at around USD 1.68 billion in 2025 and is projected to reach USD 10.32 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 35.33% during the forecast period, i.e., 2026-32.

Asthma & chronic obstructive pulmonary disease (COPD) are the most in the world responsible for high mortality rates. Ultimately, the need for AI in assessing the role of abnormally expressed genes & identifying potential novel targets for life-changing precision medicines has been greater than before. As a result, the Market has been experiencing positive growth trends. For instance, in 2024, the World Health Organization reported that COPD remains the fourth leading cause of death globally, causing 3.5 million deaths (5% of total) in 2021. Nearly 90% of premature deaths occur in LMICs, with smoking and household air pollution as major risk factors.

Further, the number of genomic research projects has been increasing with significant funding from government & private research bodies. Such research projects collect large volumes of genomic datasets and thereby make it easier for scientists to develop tailored treatments with enhanced efficacy & minimal side effects. This eventually drives the adoption of AI to analyze the vast amount of genomic & clinical data to understand the genetic basis of disease & develop precision treatments. As a result, the market for AI in Precision Medicine has been expanding globally. For instance,

• In 2025, the Government of India inaugurated the Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu, focused on integrating genomic data with advanced diagnostics to improve early detection and personalized treatment strategies.
• In 2025, the Government of Sweden announced new funding of SEK 80 million (Swedish kronor) to support Genomic Medicine Sweden (GMS), aimed at advancing and sustainably implementing precision medicine, including genomics research for cancer, rare diseases, and other health areas.

Moreover, in recent times, realizing the importance of AI & precision medicine in improving patient health outcomes, the governments of countries like the UK, India, Germany, and others have been increasingly investing in artificial intelligence (AI) technologies to support the development of novel precision medicine treatments for diseases like cancer, dementia, etc. For instance,

• In March 2025, the Government of Canada launched the Canadian Precision Health Initiative (CPHI) with a total investment of US $200 million, including government funds, to build the nation’s largest human genomic database of over 100,000 genomes and drive precision health research, enabling AI-powered analysis for personalized treatments and genomic discovery.

Global Artificial Intelligence (AI) in Precision Medicine Industry Recent Developments:

• 2025: Illumina and Tempus AI announced a strategic collaboration to advance the clinical adoption of next-generation sequencing (NGS) technologies. The partnership combines Illumina’s AI capabilities with Tempus’s multimodal data platform to develop and train genomic algorithms, accelerating the integration of AI-enhanced genomic insights into clinical practice.
• 2025: Guardant Health and ConcertAI announced a collaboration to offer the industry’s first multi-modal real-world data (RWD) solution that integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling across all stages of cancer care. This initiative is intended to support AI-driven oncology research and precision therapy development.
• 2024: Zephyr AI raised funding of USD111 million to advance it’s to advance its artificial intelligence (AI) platform for precision medicine.

Global Artificial Intelligence (AI) in Precision Medicine Market Scope:

Global Artificial Intelligence (AI) in Precision Medicine Market Driver:

High Rates of Different Cancers to Impact the Market Positively

Throughout the world, there have been high rates of various cancers, including breast & stomach. However, the currently available treatments like chemotherapy, radiation therapy, and others have not been very effective for every patient while some had negative consequences on the health of patients. There has been continuous research & development for therapies specifically tailored according to patient’s characteristics, and prove to be more effective compared to conventional treatments with minimal cost and no side effects.

Subsequently, Artificial intelligence (AI) in precision medicine has accelerated the analysis of vast amounts of genomic or proteomic data rapidly, identifying disease targets, and rapid discovery and development of drugs thereby expanding the market size for AI in Precision Medicine. For instance, according to a global analysis cited in Cancer Progress Report 2025, there were an estimated 20 million new cancer cases worldwide in 2025, with over 10.3 million deaths from cancer.

Global Artificial Intelligence (AI) in Precision Medicine Market Trend:

Increasing AI Utilization for Identifying Tailored Therapies for Rare Disease Patients

There has been a lack of treatments available for nearly all known rare disorders of the liver, muscle, and central nervous system. As healthcare is revolving & newer technologies like AI have become accessible, the focus has shifted towards developing precision genetic medicines for patients with such rare conditions. Precision medicine when utilized along with AI allows researchers to better understand the fundamental biology of rare diseases, identify new molecular drug targets, and more importantly accelerate the pace of drug discovery & development for new treatment options. Ultimately, major pharmaceutical players like Pfizer, Astra Zeneca, and others have been actively leveraging AI technologies for the research & development of precision medicine for rare diseases. Moreover, increasing government support through policy initiatives and global health resolutions to improve patient access to rare disease treatments is expected to accelerate AI adoption in precision medicine for rare conditions. For instance,

• In May 2025, at the 78th World Health Assembly, member states of the World Health Organization adopted a landmark resolution recognizing rare diseases as a global health priority, urging countries to integrate rare diseases into national health strategies, strengthen early diagnosis, enhance data systems, and accelerate research and treatment access worldwide.

Hence, as the focus of companies & governments increases on developing tailored therapies for rare disease patients, the market for Artificial Intelligence (AI) in Precision Medicine would be registering positive growth trends.

Global Artificial Intelligence (AI) in Precision Medicine Market Opportunity:

Integration of Multi-Omics Data with AI for Targeted Therapy Development

The most significant opportunity driving robust growth in the AI in precision medicine market is the integration of multi-omics data (genomics, proteomics, transcriptomics, and metabolomics) with advanced AI algorithms to enable highly targeted therapy development. As large-scale sequencing initiatives and biobanks continue to expand globally, healthcare systems are generating vast and complex biological datasets that traditional analytical tools struggle to interpret efficiently.

AI-driven platforms are increasingly being deployed to convert these multidimensional datasets into clinically actionable insights, thereby improving biomarker identification, disease risk prediction, and therapy matching. For instance,

• In April 2024, iCarbonX, founded by genomics scientist Jun Wang, demonstrated this approach by integrating genomic, metabolic, microbiome, clinical, lifestyle, and environmental data through advanced AI and machine learning models to generate personalized health profiles and targeted treatment insights.

Such developments validate the commercial viability of multi-omics–AI convergence and reinforce Asia-Pacific’s growing influence in AI-enabled precision healthcare. Consequently, the integration of multi-omics infrastructure with scalable AI analytics is emerging as a transformative growth engine, creating substantial clinical and market expansion opportunities across oncology, rare diseases, and advanced therapeutics.

Global Artificial Intelligence (AI) in Precision Medicine Market Challenge:

Ethical and Regulatory Challenges with AI to Impact Market Growth  

AI has great potential and advancement in precision medicine, but the approach has certain ethical & regulatory challenges that have been hindering its widespread adoption. The ethical challenges concerning patient privacy and surveillance, bias, and discrimination, and the role of human judgment have been restricting concerned healthcare authorities, researchers, and many medical practitioners from relying upon such technologies. This not only affects the revenue growth of companies that are present in the realm of Artificial Intelligence (AI) in Precision Medicine but also limits patient access to life-saving novel treatments.

Further, companies need to comply with certain regulatory challenges; however, due to a lack of policies & guidelines in earlier times regarding AI, authorities like the US FDA, EMA, and others have been regularly updating the regulations as per the present requirements. The regular updates have made it complicated for companies, especially those with limited budgets & resources, to comply with regulations. As a result, they either face the issues of product recall or fail to introduce their newer software & services. Ultimately, the Global Market for Artificial Intelligence (AI) in Precision Medicine faces negative growth patterns.

Global Artificial Intelligence (AI) in Precision Medicine Market (2026-32): Segmentation Analysis

The Global Artificial Intelligence (AI) in Precision Medicine Market study of MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment. It includes predictions for the period 2026–2032 at the global level. Based on the analysis, the market has been further classified as:

Based on Component:

• Hardware
• Software
• Services

The software category lead with 45% market share of the Global Artificial Intelligence (AI) in the Precision Medicine Market in 2025. This dominance has been primarily attributed to the rising prevalence of chronic diseases such as cancer, heart failure, COPD, and other complex conditions that demand highly personalized therapeutic approaches. Conventional treatment models often fail to address patient-specific variability, thereby accelerating the shift toward AI-enabled precision treatment development.

With continuous advancements in machine learning algorithms, natural language processing, and predictive analytics, AI software solutions have significantly improved in performance, scalability, and clinical interpretability. As a result, research institutions, healthcare providers, and pharmaceutical companies are increasingly relying on AI-powered platforms to streamline biomarker discovery, patient stratification, and drug development processes. For instance:

• In May 2024, OM1 launched three new products, OM1 Orion, OM1 Lyra, and OM1 Polaris, powered by its PhenOM™ artificial intelligence-driven digital phenotyping platform. These solutions analyze large-scale real-world clinical datasets to generate actionable patient insights, thereby enhancing personalized treatment decisions and clinical research efficiency.

Such product innovations underscore the growing commercialization of AI software platforms within precision medicine. Moreover, recognizing the transformative potential of AI software, major pharmaceutical companies such as Sanofi and Pfizer have been actively collaborating with technology firms to integrate advanced AI tools into drug discovery pipelines. These partnerships aim to simplify complex R&D processes and accelerate the development of targeted therapies.

Hence, supported by technological innovation, strategic collaborations, and rising clinical demand, the software segment is expected to continue its strong growth trajectory in the coming years.

Based on Therapeutic Application:

• Oncology
• Neurological Diseases
• Cardiology
• Haematological Diseases
• Autoimmune Diseases
• Others

Based on therapeutic application, oncology is projected to dominate the Global Artificial Intelligence (AI) in Precision Medicine Market, accounting for approximately 32.5% market share in 2025. The segment’s dominance is primarily driven by the rising global cancer burden and the increasing demand for personalized treatment strategies. AI technologies play a crucial role in tumor genomics analysis, biomarker discovery, early cancer detection, radiology imaging interpretation, and therapy response prediction. The growing adoption of AI-powered companion diagnostics and targeted therapy development further strengthens oncology’s leading position. For instance,

• In September 2024, researchers from Auburn University, University of Basel, and ETH Zurich developed a novel AI-driven approach combining molecular dynamics simulation and network analysis to improve the prediction of binding sites on the PD-L1 protein, thereby accelerating the development of personalized cancer therapies.

Such advancements highlight how AI is enhancing molecular-level precision in oncology drug discovery. Moreover, continued investments from pharmaceutical companies and research institutions in AI-enabled cancer research and precision oncology platforms are expected to further reinforce oncology’s substantial market share and sustained growth trajectory.

Global Artificial Intelligence (AI) in Precision Medicine Market (2026-32): Regional Projection

Geographically, the Global Artificial Intelligence (AI) in Precision Medicine Market expands across:

• North America
• South America
• Middle East and Africa
• Asia-Pacific
• Europe

North America holds a leading position in the Global Artificial Intelligence (AI) in Precision Medicine Market, accounting for approximately 39% of the overall market share, making it the dominant regional contributor. This leadership is primarily driven by the high prevalence of cancer across the region, including breast, lung, and colorectal cancers, which continue to demand more advanced and personalized therapeutic approaches. Conventional treatments such as chemotherapy and radiation therapy often show variable patient responses, thereby accelerating the adoption of AI-powered precision medicine to improve treatment efficacy and survival outcomes.

Furthermore, the growing burden of neurological disorders such as dementia and Parkinson’s disease in the aging population across the United States and Canada has intensified research efforts toward personalized and targeted treatment strategies. AI technologies are increasingly being deployed to analyze complex neurological datasets, enabling improved diagnosis, risk prediction, and therapy optimization. Moreover, strong regulatory support and continuous product innovation in the region further reinforce market expansion. For instance,

• In April 2024, Prenosis received De Novo marketing authorization from the U.S. Food and Drug Administration for its Sepsis ImmunoScore™, an AI-driven software designed to support precision diagnosis and risk prediction for sepsis.
• In February 2025, Ibex Medical Analytics secured FDA 510(k) clearance for Ibex Prostate Detect, an AI-based diagnostic tool that generates heatmaps to help identify small or rare prostatic cancers, thereby enhancing diagnostic accuracy and clinical confidence.

In addition, widespread adoption of electronic health records (EHRs) across major healthcare systems in North America has created vast repositories of clinical and genomic data. The availability of such structured and longitudinal datasets provides a strong foundation for AI-driven analytics, biomarker discovery, and patient stratification. Consequently, the integration of advanced AI platforms with robust healthcare infrastructure continues to reinforce North America’s dominant 39% market share in the AI in precision medicine industry.

Gain a Competitive Edge with Our Global Artificial Intelligence (AI) in Precision Medicine Market Report

• Global Artificial Intelligence (AI) in Precision Medicine Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
• This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
• Global Artificial Intelligence (AI) in Precision Medicine Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.